Clinical Trial Update: Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies [Phase 1]

View source ↗

Summary

Phase 1 study of STRO-001, an anti-CD74 antibody-drug conjugate, in advanced B-cell malignancies has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Indolent Lymphoma
• Mantle Cell Lymphoma
• Multiple Myeloma
• Non-hodgkin Lymphoma

Drugs mentioned

• STRO-001

Snippet

Sponsor: Sutro Biopharma, Inc. | Conditions: B-cell Lymphoma, Non Hodgkin Lymphoma | Phase 1 | Status: COMPLETED